{"id":"ep2006","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201567","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EP2006 is designed as a biosimilar to recombinant human erythropoietin (epoetin alfa), which mimics the natural hormone that regulates red blood cell production. By binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes their proliferation and differentiation, increasing hemoglobin and red blood cell counts. This mechanism is used therapeutically to treat anemia in patients with chronic kidney disease, cancer patients receiving chemotherapy, and other conditions associated with low red blood cell production.","oneSentence":"EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:15.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia in patients with chronic kidney disease"},{"name":"Chemotherapy-induced anemia in cancer patients"}]},"trialDetails":[{"nctId":"NCT01516736","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-03","conditions":"Chemotherapy-induced Neutropenia, Breast Cancer","enrollment":308},{"nctId":"NCT01735175","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-06","conditions":"Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia","enrollment":316},{"nctId":"NCT01859637","phase":"PHASE4","title":"Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia","status":"TERMINATED","sponsor":"Sandoz","startDate":"2011-07","conditions":"Severe Chronic Neutropenia","enrollment":6},{"nctId":"NCT01519700","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim","status":"COMPLETED","sponsor":"Sandoz","startDate":"2011-12","conditions":"Chemotherapy Associated Neutropenia, Breast Cancer","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Filgrastim"],"phase":"phase_3","status":"active","brandName":"EP2006","genericName":"EP2006","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia in patients with chronic kidney disease, Chemotherapy-induced anemia in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}